Fig 1.
Process and results of study selection.
Table 1.
Characteristics of included studies.
Fig 2.
Risk of bias graph.
Fig 3.
Risk of bias summary.
Fig 4.
Forest plot of incidence of composite endpoint in ticagrelor and clopidogrel group.
Fig 5.
Funnel plots for the assessment of publication bias.
(A) Incidence of composite endpoint; (B) Incidence of myocardial infarction; (C) Incidence of cardiovascular death; (D) Incidence of stroke; (E) Platelet reactivity 6 hours after administration; (F) Platelet reactivity 8 hours after administration; (G) Platelet reactivity at maintenance dose; (H) Incidence of bleeding events; (I) Incidence of dyspnea.
Fig 6.
Scatter plots of meta-regression analysis.
(A) Incidence of composite endpoint; (B) Incidence of myocardial infarction; (C) Incidence of cardiovascular death; (D) Incidence of stroke; (E) Platelet reactivity 6 hours after administration; (F) Platelet reactivity 8 hours after administration; (G) Platelet reactivity at maintenance dose; (H) Incidence of bleeding events; (I) Incidence of dyspnea.
Fig 7.
Forest plots of MI, CVD and stoke.
(A) Incidence of myocardial infarction; (B) Incidence of cardiovascular death; (C) Incidence of stroke.
Fig 8.
Forest plots of platelet reactivity.
(A) Platelet reactivity 6 hours after administration; (B) Platelet reactivity 8 hours after administration; (C) Platelet reactivity at maintenance dose.
Fig 9.
Forest plots of safety endpoint.
(A) Incidence of bleeding events; (B) Incidence of dyspnea.